Metastatic prostate cancer rising in the US
Is the drop in PSA testing to blame for a steady increase in aggressive disease?
Is the drop in PSA testing to blame for a steady increase in aggressive disease?
The first interim results of ENZAMET have been reported by an Australian-led team.
Outcomes depend on age, type of therapy and sexual function before treatment, researchers say.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.